期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports 被引量:2
1
作者 Jing-Tao Gao Li Xie +6 位作者 Li-Ping Ma Wei Shu Li-Jie Zhang yu-jia ning Shi-Heng Xie Yu-Hong Liu Meng-Qiu Gao 《World Journal of Clinical Cases》 SCIE 2021年第10期2326-2333,共8页
BACKGROUND Bedaquiline is among the prioritized drugs recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis(XDRTB).Many patients have not achieved better clinical im... BACKGROUND Bedaquiline is among the prioritized drugs recommended by the World Health Organization for the treatment of extensively drug-resistant tuberculosis(XDRTB).Many patients have not achieved better clinical improvement after bedaquiline is stopped at 24 wk.However,there is no recommendation or guideline on bedaquiline administration beyond 24 wk,which is an important consideration when balancing the benefit of prognosis for XDR-TB against the uncertain safety concerning the newer antibiotics.CASE SUMMARY This paper reported 2 patients with XDR-TB(a female of 58 years of age and a female of 18 years of age)who received bedaquiline for 36 wk,as local experience to be shared.The 2 cases had negative cultures after 24 wk of treatment,but lung imaging was still positive.After discussion among experts,the consensus was made to bedaquiline prolongation by another 12 wk.The 36-wk prolonged use of bedaquiline in both cases achieved a favorable response without increasing the risk of cardiac events or new safety signals.CONCLUSION Longer regimen,including 36-wk bedaquiline treatment,might be an option for patients with XDR-TB.More studies are needed to explore the effectiveness and safety of prolonged use of bedaquiline for 36 wk vs standard 24 wk in the treatment of multidrug-resistant/XDR-TB or to investigate further the biomarkers and criteria indicative for extension of bedaquline to facilitate clinical use of thisnovel drug. 展开更多
关键词 Pulmonary tuberculosis Bedaquiline Extensively drug-resistant tuberculosis TUBERCULOSIS Case report
下载PDF
Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China:focus on the safety 被引量:11
2
作者 Jing-Tao Gao Juan Du +40 位作者 Gui-Hui Wu Yi Pei Meng-Qiu Gao Leonardo Martinez Lin Fan Wei Chen Li Xie Yu Chen Hua Wang Long Jin Guo-Bao Li Pei-Lan Zong Yu Xiong Qian-Hong Wu Ming-Wu Li Xiao-Feng Yan Yan-Fang Miao Qing-Shan Cai Xin-Jie Li Da-Peng Bai Shu-Jun Geng Guo-Li Yang Pei-JunTang Yi Zeng Xiao-Hong Chen Tong-Xia Li Cui Cai Yun Zhou Ma Zhuo Jian-Yun Wang Wen-Long Guan Lin Xu Ji-Chan Shi Wei Shu Li-Li Cheng FeiTeng yu-jia ning Shi-Heng Xie Yu-Xian Sun Li-Jie Zhang Yu-Hong Liu 《Infectious Diseases of Poverty》 SCIE 2021年第2期75-76,共2页
Background:World Health Organization recommends countries introducing new drug and short treatment regimen for drug resistant tuberculosis(DR-TB)should develop and implement a system for active pharmacovigilance that ... Background:World Health Organization recommends countries introducing new drug and short treatment regimen for drug resistant tuberculosis(DR-TB)should develop and implement a system for active pharmacovigilance that allows for detection,reporting and management of adverse events.The aim of the study is to evaluate the frequency and severity of adverse events(AEs)of bedaquiline-containing regimen in a cohort of Chinese patients with multidrug-resistant(MDR)/extensively drug-resistant(XDR)-TB based on active drug safety monitoring(aDSM)system of New Drug Introduction and Protection Program(NDIP). 展开更多
关键词 TUBERCULOSIS MULTIDRUG-RESISTANT Bedaquiline SAFETY Surveillance program China
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部